R&D | April 22, 2026
Leinco and CellCarta team up to power next-gen proteomics for cancer and targeted therapies
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based materials
Policy symposium in Hyderabad focuses on life skills education and community?driven solutions
The programme integrates simulation-based training, expert-led sessions, and case-based discussions
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
Subscribe To Our Newsletter & Stay Updated
